Last reviewed · How we verify
NCT04963907
Alpha-Stim AID and Major Depressive Disorder
NA trial testing Active Alpha-Stim CES in Depressive Disorder, Major in 230 participants. Status unknown.
31 March 2022
Quick facts
| Lead sponsor | Electromedical Products International, Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 230 |
| Start date | 5 January 2021 |
| Primary completion | 31 March 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Active Alpha-Stim CES
- Sham Alpha-Stim CES
Conditions studied
- Depressive Disorder, Major — all drugs for Depressive Disorder, Major →
Sponsor
Electromedical Products International, Inc. — full company profile →
Who can join
16 and older, any sex, with Depressive Disorder, Major. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will be a multi-centre parallel group, double blind, non-commercial, randomised controlled superiority trial. Study participants will be referred from Primary Care GP practices via their GP and randomised into active Alpha-Stim AID Cranial Electrotherapy Stimulations (CES) or sham Alpha-Stim AID CES.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124
Verify or expand the search:
- PubMed search for NCT04963907
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depressive Disorder, Major
Currently open trials in the same condition.
- NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
- NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
- NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
- NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
- NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting
Other Electromedical Products International, Inc. trials
Trials by the same sponsor.
- NCT06124014 — CES for the Treatment of GAD in Young Adults · NA · completed
- NCT05772702 — Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Depression · NA · completed
- NCT04587531 — Neural Mechanisms With CES in Depression · NA · terminated
- NCT03222752 — Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04963907 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Electromedical Products International, Inc.
- Last refreshed: 15 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04963907.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing